[Steroid - induced osteoporosis]

Area of Science:

• Biomedical Science
• Molecular Biology
• Orthopedics

Context:

• Glucocorticoids are widely used for their anti-inflammatory properties but are associated with significant skeletal side effects.
• Osteoporosis and femoral osteonecrosis are critical bone lesions linked to corticosteroid therapy.
• Steroid-induced bone pathologies impact osteoblast function and bone marrow microenvironment.

Purpose:

• To investigate the molecular mechanisms underlying steroid-induced bone lesions, specifically osteoporosis and femoral osteonecrosis.
• To explore the role of endothelial cell dysfunction and apoptosis in steroid-induced femoral osteonecrosis.
• To evaluate the potential of alendronate in managing steroid-induced osteoporosis.

Summary:

• Corticosteroids inhibit osteoblastogenesis by promoting osteoblast apoptosis and reducing osteoblast activity.
• Molecular insights reveal steroid-induced decreases in Cbfa1 and TGF-beta type I receptor expression.
• Steroid treatment also induces endothelial cell dysfunction and apoptosis within bone marrow tissues, contributing to femoral osteonecrosis.
• Alendronate is emerging as a therapeutic option for improving bone quality in steroid-induced osteoporosis.

Impact:

• Provides a deeper understanding of the molecular pathogenesis of steroid-induced bone diseases.
• Highlights the dual impact of steroids on bone cells and vascular endothelium.
• Suggests alendronate as a potential therapeutic strategy for mitigating steroid-induced skeletal complications.
• Informs clinical management of patients receiving long-term corticosteroid therapy.